Immutep Limited Stock Current Ratio

PRRUF Stock  USD 0.20  0.00  0.00%   
Immutep Limited fundamentals help investors to digest information that contributes to Immutep's financial success or failures. It also enables traders to predict the movement of Immutep Pink Sheet. The fundamental analysis module provides a way to measure Immutep's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immutep pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Immutep Limited Company Current Ratio Analysis

Immutep's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Immutep Current Ratio

    
  14.16 X  
Most of Immutep's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immutep Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, Immutep Limited has a Current Ratio of 14.16 times. This is 386.6% higher than that of the Healthcare sector and 102.29% higher than that of the Biotechnology industry. The current ratio for all United States stocks is notably lower than that of the firm.

Immutep Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immutep's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics of similar companies.
Immutep is currently under evaluation in current ratio category among its peers.

Immutep Fundamentals

About Immutep Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immutep Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Immutep Pink Sheet

Immutep financial ratios help investors to determine whether Immutep Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immutep with respect to the benefits of owning Immutep security.